A Phase 3, Randomized, Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sacituzumab Tirumotecan Maintenance Treatment With Or Without Bevacizumab Versus Standard Of Care After Second-Line Platinum-Based Doublet Chemotherapy In Particip
Posted Date: Mar 17, 2025
- Investigator: Thomas Herzog
- Specialties:
- Type of Study: Drug
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Criteria:
Patients With Adequate Performance Status (0-1) Who Are At First Recurrence For Platinum-Sensitive Recurrent Ovarian Cancer And Who Received At Least 4 Cycles Of Platinum-Based Therapy In Front-Line Treatment Are Eligible.
Keywords:
Ovarian Cancer, Platinum-Sensitive, Adc
For More Information:
Thomas J Herzog Md
NULL
thomas.herzog@uc.edu